I rarely watch commercials anymore, but recently my husband and I were catching up on one of our favorite shows when an Ozempic ad came on. It wasn’t the classic “O-O-Ozempic” jingle. Instead, a deep voice was singing, “There’s a pill version of Ozempic.” I was half paying attention until my brain caught up with what I had just heard.
Wait. There’s an Ozempic pill? And before the commercial was over, my husband had pointed out something else that stuck with me: what looked, at least to us, like a subtle layer of weight bias in how the people in the ad were visually presented. Not to mention the “Ozempic guy” was the “Dude, get a Dell!” Guy. Whhhhhhat?!
Admittedly, I sometimes spend an unreasonable amount of time following the GLP-1 market & news because I’m an obesity care advocate. I interview doctors and researchers on The Plus SideZ Podcast, read studies and industry news, and talk about these medications every day.
Somehow, I had missed that Ozempic tablets became available in the U.S. in May 2026. In all fairness, my sister passed away in March So I’ve been pretty disconnected. But that’s another Substack for another day.
Naturally, I started Googling.
Was this basically Rybelsus, which is far from new?
Was it using the newer oral semaglutide technology I remembered hearing about with the Wegovy pill?
How does a pill compare with the Ozempic shot?
And to my husband’s observation, what’s up with this psychological twist on body size for the GLP-1 guy chillin in the recliner. Though later, the Ozempic pill girl was too in a different add. Eating popcorn I think.
So what is the “Ozempic” pill?
This industry does have a track record of slapping a new label on something for marketing but it’s the same ingredient as the original. The connection to Rybelsus is pretty direct. Rybelsus has been oral semaglutide for type 2 diabetes since 2019, and the new Ozempic tablets are also oral semaglutide for adults with type 2 diabetes. The newer tablets use an updated formulation that allows more semaglutide to reach the bloodstream.
That’s an important distinction because hearing “Ozempic pill” makes it sound like someone simply took what was in the pen and put it into a tablet. Getting semaglutide to work orally is much more complicated than that.
Semaglutide is a peptide, and our digestive system is very good at breaking peptides down. Helpful when we eat dinner, but less helpful when the peptide is the medication we are trying to absorb.
Oral semaglutide uses an absorption enhancer called SNAC (punny), or salcaprozate sodium. SNAC helps semaglutide survive long enough in the stomach to be absorbed through the stomach lining. Rybelsus already used SNAC, so this technology is not brand new. What has improved is the formulation and how efficiently the medication is absorbed.
According to FDA information, the older Rybelsus formulation had estimated bioavailability of roughly 0.4% to 1%. The newer Ozempic tablet formulation is estimated at around 1% to 2%. Those numbers sound tiny because oral semaglutide is still difficult to absorb, but improving that percentage matters when you are working with a peptide pill.
Here’s what’s crazy!
The newer formulation didn’t add a new absorption enhancer. Instead, they actually removed some ingredients, a filler and a binder, while keeping the semaglutide plus SNAC tech. And that tweak improved bioavailability enough that lower doses of the newer tablet give similar exposure to higher doses of the older one. It’s wild to me that subtraction was the actual innovation because it’s usually the other way around.
This is also the connection I remembered from the Wegovy pill. The newer Wegovy tablets use the same general oral semaglutide approach, so my memory was partly right. I had just mentally filed the whole thing under “new Wegovy pill technology” when the story actually started with Rybelsus and continued evolving from there. Oops. lol
There is one very Rybelsus-like detail that remains. The Ozempic pill still needs to be taken on an empty stomach with a small amount of plain water, followed by at least 30 minutes before food, other drinks or oral medications. We have improved the science. Coffee remains unwilling to compromise. So annoying.
How does the Ozempic pill compare with the shot?
At a high level, both contain semaglutide, but our bodies handle oral and injected semaglutide differently. That means the milligram numbers on the tablet do not translate neatly to the numbers patients are used to seeing on an Ozempic pen.
There is detailed FDA guidance for clinicians on dosing and switching between certain formulations, but that is well outside my lane as an advocate. For patients, I think the more useful questions are whether your current treatment is working, whether you prefer a daily pill or weekly injection, whether the morning fasting routine fits your life, and what your insurance will actually cover. Your prescriber can handle the conversion math.
For anyone who wants the dosing details, the FDA prescribing information for Ozempic tablets lays all of that out.
Then my husband pointed something out…
The commercial was entertaining. It had this game-show-style setup where Ozempic was being compared with a broad category of “other GLP-1s,” rather than one specific medication.
My husband noticed something before I did. He is autistic and sometimes catches visual details and patterns that sail right past me. He pointed out that the people associated with Ozempic appeared leaner and more conventionally fit, while the man representing the broader GLP-1 category had a larger, huskier body.
Once he said it, I saw what he meant. I have no idea whether that casting decision was intentional, and I would not claim that it was. What interested me was the impression it could create without anyone having to say anything directly.
That feels especially relevant with Ozempic because it is approved for type 2 diabetes, while Wegovy is Novo Nordisk’s semaglutide brand for chronic weight management. Yet Ozempic is so culturally connected to weight loss that body size in an Ozempic commercial can carry meaning whether the script talks about weight or not.
And that is where the ad became more interesting to me than the pill…
The FDA has already questioned the campaign’s visual framing
Ruh Roh. When I looked into the broader campaign, I found that the FDA had already raised concerns about a different Ozempic ad from the same campaign. In a February 2026 letter to Novo Nordisk, the agency said the overall presentation could leave viewers with the impression that Ozempic was superior to other GLP-1 medications, even though the studies being referenced did not establish that kind of superiority.
What caught my attention was that the FDA did not limit its criticism to the spoken claims. It specifically mentioned visual choices, including the Ozempic character wearing bright orange while the “other GLP-1s” character wore dull gray. The agency said those choices contributed to the overall impression being created by the ad.
The FDA did not comment on body size in the commercial my husband and I watched. That observation is ours. Still, it made me think about how much we absorb from pharmaceutical advertising before we consciously evaluate the words.
Casting, clothing, color, humor, body size and who appears healthier or more successful can all shape how a viewer interprets an ad. I would call that psychological framing. It is a normal part of advertising, but prescription drug advertising deserves a little more scrutiny because the people watching may be making decisions about their health.
That is ultimately what stuck with me. I started out surprised that there was an Ozempic pill and ended up thinking about two different kinds of absorption: how semaglutide gets through the stomach, and how advertising gets into our heads.
The science behind oral semaglutide has improved, and having another way to take the medication could matter for patients who want an alternative to injections. The commercial that finally told me about it also turned out to be a pretty good reminder to pay attention to what an ad is showing us, not only what it says.
My take on Future Pharma Commercials
It may shock you that I think we need them. Too many meds come out in and aren’t mentioned in a 10 min appointment with a PCP. And I think it’s good for us to see it, research it, take that insight to our doctor and be part of our own care team.
But I think more care should be taken to educate both that obesity and type 2 diabetes are chronic, progressive diseases. Educate people on why they need the med to begin with!
You may think people know, but I can tell you that as someone who speaks to hundreds of people a day who have this disease most of them do not. They think that they are fat, lazy, and they should’ve put the fork down. They don’t understand that 40 to 70% of your weight is predetermined by genetics. They don’t understand that obesity causes the over eating, The over eating doesn’t cause obesity.
Unfortunately, I think that we are still pretty far away from society, accepting obesity as a disease And removing any kind of accountability from someone who has it. But a lot of my work is focused on this.
If you’ve got someone’s attention for 30-60 seconds, which maybe could do more than spread alleged stigma bias we’re all trying to combat. Take the opportunity to teach about the disease and empower patients. Drop with what seem like tampon commercials for medicine.
While I found the new commercials entertaining, I think there’s a bigger opportunity to educate & I hope big pharma takes this note.
But I’m curious what you think. Tell me in the comments.
Sources
FDA approval letter for Ozempic tablets / Rybelsus formulation change
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf
FDA prescribing information for Ozempic tablets
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf
Novo Nordisk announcement on U.S. Ozempic pill availability
https://www.novonordisk-us.com/media/press-releases/ozempic-pill-us-availability-type-2-diabetes.html
FDA February 2026 letter regarding Ozempic advertising
https://www.fda.gov/media/191387/download
Research on SNAC and gastric absorption of oral semaglutide
https://pubmed.ncbi.nlm.nih.gov/30429357/
WHO: Obesity and overweight
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
American Diabetes Association, Standards of Care in Diabetes 2026
https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes
